Iron Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Iron dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Iron.
Dosing Protocols
The Beginner Protocol addresses the most common iron scenarios in practice: suspected or mild confirmed iron deficiency in a premenopausal woman, restless legs with low ferritin, or post-bariatric maintenance. Start with confirmatory labs: ferritin (the most sensitive marker of iron stores; < 30 ng/mL indicates iron deficiency and <15 ng/mL is diagnostic without need for further testing in most contexts), complete blood count (hemoglobin, MCV), and ideally transferrin saturation and CRP to distinguish true iron deficiency from anemia of chronic disease. Women with heavy menstrual bleeding often require chronic supplementation regardless of initial ferritin. Dose 40–80 mg elemental iron once daily (one 325 mg ferrous sulfate tablet = 65 mg elemental, or one Ferrochel bisglycinate tablet = typically 25–45 mg elemental), or equivalently 120 mg on alternate days (which may be more efficient per Stoffel et al. 2017). Take with 250 mg vitamin C on an empty stomach if tolerated, or with a small meal if GI-sensitive. Separate from coffee/tea/milk by 1+ hour, from calcium and zinc supplements by 2+ hours, from thyroid medications and antibiotics as detailed in side effects. Duration 3–6 months minimum; recheck ferritin and CBC at 3 months, and continue until ferritin is comfortably above 50 ng/mL. For RLS specifically, target ferritin > 75 ng/mL and transferrin saturation > 20% as per international consensus. Pregnancy: WHO recommends 30–60 mg/day elemental iron for all pregnant women in iron-deficient regions; in the US, iron-containing prenatal vitamins covering 27 mg/day are standard, with higher doses added only for confirmed deficiency. Infants: consult pediatrician; iron-fortified formula and iron-rich first foods are the foundation. Adult men and postmenopausal women should NOT use the Beginner Protocol "just to cover bases" — iron supplementation in this population without confirmed deficiency is not appropriate given lack of regulated excretion and risk of unmasking hemochromatosis. If you are a healthy adult man or postmenopausal woman with a multivitamin containing iron and no confirmed deficiency, consider switching to an iron-free multivitamin.
The Intermediate Protocol addresses confirmed iron-deficiency anemia, iron deficiency without anemia in symptomatic women, heavy menstrual bleeding, athletic deficiency, or post-bariatric deficiency requiring more aggressive repletion. Begin with full iron panel: ferritin, CBC, transferrin saturation, TIBC, reticulocyte count, and CRP. For iron-deficiency anemia with hemoglobin typically <11 g/dL in women or <13 g/dL in men (with confirmed iron deficiency), target 100–200 mg elemental iron daily split to improve tolerance — or equivalently 120 mg/day on alternate days if tolerance of split dosing is poor. Forms with better tolerance for higher doses: ferrous bisglycinate (Ferrochel, 25–45 mg elemental per capsule), ferric maltol (Accrufer, 30 mg elemental per capsule), heme iron polypeptide (Proferrin, 11 mg heme iron per tablet — less GI toxicity but more expensive). Standard ferrous sulfate/fumarate/gluconate are effective if tolerated. Pair with 250 mg vitamin C at each dose; ensure copper and B12/folate sufficiency if anemia doesn't respond by 3–4 weeks. Assess response at 1 month: reticulocyte count and hemoglobin should rise; ferritin rises later. If no response, evaluate for persistent blood loss (GI evaluation in men or postmenopausal women, menstrual evaluation in premenopausal women), malabsorption, inflammation (check CRP, evaluate for IBD/celiac), or pill-swallowing issues. If oral iron fails or is poorly tolerated despite protocol optimization, IV iron is a reasonable next step — ferric carboxymaltose (Injectafer, 750 mg IV over 15+ minutes, can be repeated in 1 week for total 1,500 mg; or 1,000 mg IV for some protocols), iron sucrose (200 mg IV over 5+ minutes, repeated to cumulative dose), or ferumoxytol (510 mg IV over 30+ minutes, repeated in 3–8 days). IV iron delivered in appropriate clinical setting with monitoring for hypersensitivity. Duration of oral therapy: typically 3–6 months beyond hemoglobin normalization to fully replete ferritin. For heavy menstrual bleeding patients who can't avoid ongoing monthly losses, chronic maintenance iron supplementation at 40 mg elemental/day or alternate-day 60–120 mg is often needed indefinitely.
The Advanced Protocol covers complex iron management: heart failure with iron deficiency, chronic kidney disease anemia, inflammatory bowel disease anemia, chronic anemia of inflammation, post-bariatric refractory deficiency, and iron overload syndromes. Heart failure with iron deficiency: FAIR-HF, CONFIRM-HF, AFFIRM-AHF trials established ferric carboxymaltose IV (Injectafer) as guideline-supported therapy for symptomatic HF with iron deficiency (ferritin <100 or ferritin 100–300 with transferrin saturation <20%) regardless of hemoglobin (PMID 19920054, 26034145, 33245868). Dosing is based on body weight and hemoglobin deficit, typically 500–1,000 mg total repeated every 6–12 months. CKD anemia: iron management integrates with erythropoiesis-stimulating agents (ESAs); IV iron sucrose or ferumoxytol are standard in dialysis with specific target ferritin and transferrin saturation ranges. IBD anemia: oral iron is often poorly tolerated and can worsen intestinal inflammation; ferric maltol (Accrufer) has approval specifically for IBD, and IV iron (ferric carboxymaltose, iron sucrose) is widely used with good efficacy and tolerance. Post-bariatric refractory iron deficiency is common after Roux-en-Y and often requires annual or bi-annual IV iron given persistent malabsorption. Anemia of chronic inflammation (functional iron deficiency with elevated hepcidin from IL-6/inflammation): addressing the underlying inflammation is primary; IV iron can be used to bypass the mucosal block but response may be limited until inflammation is controlled. Hereditary hemochromatosis: phlebotomy is the gold standard — weekly 500 mL phlebotomy removes ~200 mg iron, continued until ferritin drops below 50 ng/mL (typically 1–3 years for newly diagnosed C282Y homozygotes), then maintenance phlebotomy every 2–4 months to keep ferritin under 50 ng/mL. Early diagnosis and phlebotomy before cirrhosis develops restores near-normal life expectancy. Iron chelation (deferoxamine IV/SC, deferasirox oral, deferiprone oral) is used in transfusional iron overload in thalassemia major and MDS, specialist-managed. Athletic iron deficiency (endurance runners especially, with both hematologic and brain iron deficiency affecting performance and mood): aggressive repletion with oral iron plus vitamin C, sometimes IV iron if oral fails, targeting ferritin >50 for general athletes and >75 for RLS-prone patients. Pregnancy severe anemia: IV iron is now commonly used in second and third trimester for severe anemia or when oral iron fails, with ferric carboxymaltose and iron sucrose both having good safety records in pregnancy. The Advanced Protocol is defined by specialist involvement, lab-guided protocol adjustment, awareness of hepcidin physiology in designing oral vs IV strategy, and recognition that iron management is rarely a one-size-fits-all problem.
Commonly Stacked With
Iron's stacking logic centers on absorption optimization, trace mineral partnerships, and drug separation. The foundational absorption enhancer is Vitamin C — ascorbate reduces Fe³⁺ to Fe²⁺ at the duodenal brush border and maintains iron solubility in the more alkaline small intestinal environment, and co-administration of 100–250 mg vitamin C roughly doubles non-heme iron absorption. This is one of the highest-leverage stacking rules in nutrition: if you take iron, take vitamin C with it. Orange juice, bell peppers, strawberries, or a 250 mg vitamin C tablet all work. Iron and Copper are linked through ceruloplasmin, the copper-dependent ferroxidase that oxidizes Fe²⁺ to Fe³⁺ for transferrin loading. Copper deficiency causes anemia that looks like iron deficiency but fails to respond to iron alone; iron deficiency in a copper-replete patient is the far more common scenario, but in patients on chronic high-dose zinc, post-bariatric, or with inflammatory bowel disease, both iron and copper should be addressed. Dosing order does not matter — what matters is ensuring copper status before attributing non-response to iron repletion failure. Iron and Vitamin B12 and folate form the complete anemia evaluation and repletion triad; any work-up of unexplained anemia should include all three, and repletion often requires addressing multiple deficits in parallel rather than serially. Iron and Zinc: zinc competes for DMT1 transport, and high-dose zinc can reduce iron absorption. Standard RDA-range zinc (10–15 mg/day) does not meaningfully impair iron absorption, but pharmacologic zinc (50+ mg/day) should be separated from iron by 2+ hours. Iron and Vitamin D: some data suggest vitamin D modulates hepcidin and iron metabolism; clinically, both deficiencies should be addressed in anemia workups, and vitamin D sufficiency may improve response to iron supplementation in deficient patients. Iron and Vitamin K2: no direct interaction. Iron and Magnesium: no direct interaction; magnesium supports many iron-containing enzymes downstream but does not interfere with absorption. Iron and calcium: calcium competes for DMT1 and reduces iron absorption when co-administered — dairy with iron meals reduces non-heme iron absorption significantly. Separate calcium-heavy meals and iron supplementation by 2+ hours, and specifically avoid taking iron with milk or a calcium-fortified beverage. Iron and coffee/tea: tannins form insoluble iron-tannin complexes and substantially inhibit non-heme iron absorption. Separate coffee/tea by 1+ hour around iron supplements. Iron and meat (heme iron + non-heme iron): heme iron enhances non-heme iron absorption (the "meat factor"), which is why adding meat to plant-based meals improves plant iron utilization. Iron and phytates (whole grains, legumes): phytates inhibit non-heme iron absorption significantly, and this is a major reason why vegetarian iron status is harder to maintain despite similar total intake. Soaking, sprouting, fermentation, and cooking reduce phytate impact. Iron and polyphenols (some berries, red wine): mixed effects depending on specific polyphenol, generally mild inhibition. Iron and levothyroxine: separate by 4 hours; iron chelates levothyroxine and reduces absorption. Iron and tetracyclines, fluoroquinolones: separate by 2+ hours. Iron and bisphosphonates: separate by 2+ hours. Iron and NAC: NAC is a weak metal chelator at high doses but does not meaningfully deplete iron at standard antioxidant doses. Iron and CoQ10: complementary mitochondrial and energy-metabolism nutrients; no direct interaction. Iron and Omega-3 fatty acids: no direct interaction. Iron and Curcumin: curcumin has been shown to chelate iron weakly and has been explored as an adjunct in thalassemia; in iron-replete users at standard doses, no clinically significant iron depletion occurs. Iron and alternate-day dosing: based on the hepcidin mucosal block, alternate-day 120 mg elemental iron achieves similar or higher total absorption than split daily 40 mg three times daily, with better GI tolerance. This has become the evidence-based protocol for oral iron therapy in non-urgent mild-moderate deficiency. Iron timing: morning dosing is standard; empty stomach increases absorption but worsens GI tolerance; with food reduces absorption ~40% but improves tolerance. For most patients the pragmatic compromise is with a small snack and 250 mg vitamin C, separated from coffee, tea, milk, and other mineral supplements. The cleanest stacking synthesis: iron + vitamin C on alternate days, separated from calcium/coffee/tea/thyroid meds, with copper status ensured if any ongoing failure to respond.
Side Effects & Safety
Contraindications
Iron supplementation is contraindicated or requires special caution in several settings. Hereditary hemochromatosis is an absolute contraindication for iron supplementation — affected patients cannot regulate iron absorption via hepcidin, and any additional iron accelerates organ iron loading with progression toward cirrhosis, diabetes, cardiomyopathy, and other complications. Family history of hemochromatosis (first-degree relative) or unexplained ferritin elevation in the 500–1,000+ ng/mL range in middle-aged patients should prompt HFE genetic testing before any iron supplementation. Thalassemia and sickle cell disease with chronic transfusions cause transfusional iron overload that requires chelation, not supplementation; iron supplements are contraindicated. Porphyria cutanea tarda (a photosensitive dermatosis with hepatic iron involvement) is worsened by iron and treated with phlebotomy. African iron overload (formerly called Bantu siderosis) from home-brewed beer fermented in iron vessels plus genetic susceptibility similarly contraindicates supplementation. Chronic infection, especially malaria and tuberculosis, requires caution — unrestricted iron supplementation in malaria-endemic regions has been associated with worsened malaria severity in some trials (the Pemba trial famously showed increased mortality in iron-supplemented young children in a malaria-endemic area, leading to WHO to restrict universal supplementation in these settings). Active bacterial infection: many bacteria are iron-dependent and iron supplementation during acute bacterial sepsis is generally avoided. Inflammatory bowel disease flare: oral iron can worsen intestinal inflammation and IV iron is preferred for documented iron deficiency in active IBD. Hemolytic anemia: iron supplements are not indicated; hemolysis recycles body iron efficiently and adding external iron risks loading. Aplastic anemia or myelodysplastic syndromes with transfusion dependence: iron overload is a major concern and iron supplements are contraindicated. G6PD deficiency: iron can catalyze oxidative hemolysis in theory; avoid high-dose iron supplements in G6PD patients without indication. Acute gastroenteritis or peptic ulcer disease: iron can worsen GI inflammation; consider delaying or switching to better-tolerated forms. Pregnancy: RDA-range iron (27 mg/day in prenatal vitamin, up to 60 mg for confirmed deficiency) is strongly recommended; higher doses should be evidence-based and lab-guided. Pediatric dosing: pediatrician-directed only; adult-strength iron in pediatric hands is a major poisoning risk. Peptic ulcer, hemochromatosis heterozygotes: use with caution and lab monitoring. Drug interactions: levothyroxine (separate 4 hours), tetracyclines and fluoroquinolones (separate 2 hours), bisphosphonates (separate 2 hours), methyldopa (chelation reduces absorption), levodopa (chelation reduces absorption, particularly relevant in Parkinson disease), penicillamine (chelates with iron), trientine (chelation), chloramphenicol (reduces response to iron), and PPIs/H2 blockers (reduce iron absorption, consider acidified forms or alternate-day dosing). Men and postmenopausal women should not take iron supplements without documented deficiency — this is the most important general cautionary principle, given the absence of a regulated excretion pathway and the substantial prevalence of undiagnosed hemochromatosis genetics in Northern European populations. If you are unsure whether iron supplementation is appropriate, get baseline ferritin and iron studies and discuss with a clinician rather than proceeding empirically. This is general educational content, not medical advice.
Additional Notes
Dosing iron requires distinguishing elemental iron content from the iron salt weight, which varies substantially by formulation. Ferrous sulfate 325 mg tablet = 65 mg elemental iron (iron is 20% of ferrous sulfate by mass). Ferrous sulfate 200 mg = 60 mg elemental iron (from a different salt hydration state — the UK standard dose). Ferrous fumarate 325 mg = 106 mg elemental iron (iron is 33% of fumarate by mass, higher density than sulfate). Ferrous gluconate 325 mg = 36 mg elemental iron (iron is 11% of gluconate, lower density). Ferrous bisglycinate (Ferrochel, Albion) varies by manufacturer but typically is labeled by elemental iron content directly — a "25 mg Ferrochel" capsule contains 25 mg elemental iron as the chelate. Heme iron polypeptide (Proferrin) 11 mg per tablet. Ferric maltol (Accrufer) 30 mg elemental iron per capsule. Standard oral dosing for iron-deficiency anemia: 100–200 mg elemental iron/day, historically split 3 times daily but increasingly given as alternate-day 120 mg based on Stoffel et al. evidence showing equivalent absorption with better tolerance. Mild deficiency without anemia: 40–80 mg elemental iron/day or 60–120 mg alternate-day. Pregnancy prophylaxis: 30–60 mg/day from prenatal vitamin through pregnancy and lactation. Pediatric: pediatrician-directed; infant supplementation typically 1 mg/kg/day starting at 4 months for exclusively breastfed infants. RDA is 8 mg/day for adult men, 18 mg/day for premenopausal women, 27 mg/day for pregnancy, 9 mg/day for lactation, 11 mg/day for infants 7–12 months, 7 mg/day for toddlers 1–3 years. Tolerable upper limit is 45 mg/day for adults. Take timing: on empty stomach with 250 mg vitamin C for maximum absorption; with a small snack if GI tolerance is problematic. Morning dosing is standard; separate from coffee/tea by 1+ hour, from calcium/dairy by 2+ hours, from zinc and magnesium supplements by 2+ hours, from levothyroxine by 4 hours, from tetracyclines/fluoroquinolones by 2+ hours, from bisphosphonates by 2+ hours. IV iron dosing is specialist and protocol-based: ferric carboxymaltose 750 mg or 1,000 mg per infusion, repeated in 1 week for total course; iron sucrose 100–200 mg per infusion, repeated 3–5 times for total course; ferumoxytol 510 mg per infusion repeated in 3–8 days. Total dose requirements calculated by Ganzoni formula or standardized hemoglobin-based tables. Lab monitoring for oral supplementation: baseline ferritin, CBC, transferrin saturation, CRP; recheck at 1 month for reticulocyte response, 3 months for hemoglobin response, 6 months for ferritin recovery. For maintenance, ferritin annually is reasonable. For hemochromatosis monitoring, ferritin and transferrin saturation every 2–4 months during active phlebotomy, quarterly or twice-yearly during maintenance. Form selection: ferrous sulfate remains the cheapest and first-line for most patients who tolerate it; bisglycinate, ferric maltol, and heme iron polypeptide are alternatives for those with poor tolerance; IV iron is reserved for oral failure or specific indications (HF, IBD, CKD, post-bariatric, heavy bleeding not controlled with oral). Liquid iron preparations and children's iron drops dose by elemental iron per mL — read labels carefully to avoid pediatric overdose.
Frequently Asked Questions
What is the recommended Iron dosage?
Dosage for Iron varies by protocol. Consult a qualified healthcare provider.
How often should I take Iron?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Iron need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Iron side effects?
Iron is the nutrient most likely to cause significant supplement side effects, both acute and chronic. Oral iron GI toxicity is dose-dependent and common — in placebo-controlled trials, 30–70% of patients on standard oral iron (60–120 mg/day elemental) report nausea, abdominal cramping, constipation, dark stools (harmless but often alarming), and in some cases diarrhea. This is the major reason for non-compliance with iron therapy and a major driver of switching to alternate-day dosing, lower-dose protocols, IV iron, or alternative forms (bisglycinate, ferric maltol, heme iron polypeptide) with better tolerance. Black stools from iron are a normal and expected finding; bright red blood in stool or melena beyond expected iron-related darkening is not iron, it's bleeding, and warrants evaluation. Ferrous sulfate, ferrous fumarate, and ferrous gluconate all cause GI symptoms in a similar fraction of patients; ferrous bisglycinate (Ferrochel), ferric maltol (Accrufer), and heme iron polypeptide (Proferrin) have somewhat better tolerance in head-to-head studies, at the cost of higher price. IV iron eliminates GI toxicity entirely. Acute iron toxicity from accidental overdose is a classic pediatric poisoning category — children swallowing adult-strength iron pills can develop severe hemorrhagic gastritis, shock, hepatotoxicity, and delayed metabolic acidosis; 40 mg/kg elemental iron is potentially lethal. All iron supplements must be stored in child-resistant containers out of reach of children; iron is one of the leading causes of pediatric poisoning deaths from pharmaceuticals. Chronic iron overload from inappropriate long-term supplementation is a real risk in hemochromatosis heterozygotes and undiagnosed C282Y homozygotes — roughly 1 in 200 people of Northern European ancestry have undiagnosed HFE C282Y homozygosity, and prolonged iron supplementation can hasten organ iron loading. This is the fundamental reason iron supplementation should not be taken "prophylactically" by men or postmenopausal women without documented iron deficiency. IV iron specific adverse effects: hypersensitivity reactions ranging from minor (flushing, transient chest tightness) to rare true anaphylaxis, particularly historically with iron dextran (Fishbane reactions). Newer IV iron products (ferric carboxymaltose, ferumoxytol, iron sucrose, iron isomaltoside) have much lower rates of serious hypersensitivity, but all carry some risk and IV iron should be administered where resuscitation is available. Hypophosphatemia is a specific concern with ferric carboxymaltose (Injectafer), documented in multiple trials with some patients developing symptomatic hypophosphatemia and osteomalacia with repeated dosing; monitoring phosphorus and bone effects is warranted for patients needing multiple IV iron courses. Skin discoloration at IV iron injection sites (brown staining from extravasation) is a known complication and can be prolonged. Drug interactions: iron and [Vitamin C](/compound/vitamin-c) is synergistic (enhances non-heme iron absorption). Iron and levothyroxine: iron chelates levothyroxine and reduces absorption; separate by at least 4 hours. Iron and thyroid hormone efficacy — iron deficiency impairs TPO enzyme activity and worsens hypothyroidism correction, so in iron-deficient hypothyroid patients addressing iron often improves thyroid hormone response. Iron and tetracycline, fluoroquinolone antibiotics: chelation reduces both drugs' absorption; separate by at least 2 hours. Iron and bisphosphonates: separate by 2+ hours. Iron and calcium: calcium competes for DMT1 transport; separate by 2+ hours for best iron absorption, though this is more relevant to heavy dietary calcium than low-dose calcium supplements. Iron and antacids/PPIs: reduced gastric acid reduces ferric reduction and iron absorption; consider acidified formulations (e.g., with vitamin C) or alternate-day dosing when patients are on chronic PPIs. Iron and [Alpha-Lipoic Acid](/compound/alpha-lipoic-acid): ALA weakly chelates divalent metals; clinically significant interaction at standard doses is minimal. Iron and [Copper](/compound/copper): copper is required for iron utilization via ceruloplasmin ferroxidase; iron replenishment without adequate copper status is inefficient, and copper-iron should be addressed together in complex trace mineral protocols. Iron and [Zinc](/compound/zinc): high-dose zinc and high-dose iron compete for DMT1 transport at the brush border; separate by 2+ hours if taking both therapeutically. Iron and coffee/tea: tannins inhibit non-heme iron absorption substantially; separate by 1+ hour around iron supplementation for best absorption. Iron and alcohol: chronic heavy alcohol use increases iron absorption and is additive with hemochromatosis genetics for organ injury; iron supplementation in heavy drinkers is generally inappropriate. The cleanest safety summary: iron is well-tolerated at dietary intake, GI toxicity with oral supplements is common but manageable, alternate-day dosing improves tolerance, IV iron is increasingly used for specific indications, acute overdose is a serious pediatric poisoning risk, and chronic inappropriate supplementation in men and postmenopausal women risks organ iron loading especially in undiagnosed hemochromatosis.
Where can I buy Iron?
Visit our vendor directory to find trusted sources for Iron.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
